

Clinical Trials Hematology

May
2026

Table of Contents

STENZLICO

01.

Introduction

02.

Contact

03.

Overview Clinical Trials

ALCL

ALL

AML

CLL

CML

DLBCL

FL

MCL

MDS

MF

MM

MZL

SCT

TCL

WM

Other

The overview of the clinical trials conducted at the University Hospital at the Department of Hematology can be found in this booklet.

We are proud to report that currently more than 50 trials are conducted at our department spread over 20 hematologic diseases. The trials are classified according to their hematological disease. Trials with both the "Open"- and "In startup"- status are included in this booklet.

This document is confidential and intended solely for the use of the individual or entity to whom it is addressed. If you have received this document in error, please notify the sender and delete this file from your computer. Disclosing, copying, distributing or taking any action in reliance on the contents of this document is strictly prohibited.

Feel free to contact us, if you need more information about a certain trial. You can find our contact details on the next page.

The Clinical Trial Coordinators Team

Clinical Trial Coordinators Team

General	studies.hematologie@uzgent.be
Leukemia	katrien.degrove@uzgent.be +32 9 332 14 82
Lymphoma	sofie.lust@uzgent.be +32 9 332 08 70 saskia.baert@uzgent.be +32 9 332 64 45
Multiple Myeloma	nathalie.luickx@uzgent.be +32 9 332 20 97 valerie.Haelterman@uzgent.be +32 9 332 87 70
MDS / MF	lieselot.vandepitte@uzgent.be +32 9 332 08 79

Stemcell and CAR-T Coordinators

stamceltransplantatie@uzgent.be

Amy +32 9 332 57 13

Charlotte +32 9 332 58 13

CART.hematologie@uzgent.be

Astrid +32 9 332 11 03

Physicians

Tessa Kerre, Prof. MD. - Head of department

Anna Vantilborgh, MD. - Head of department

Fritz Offner, Prof. MD.

Dominiek Mazure, MD.

Ciel De Vriendt, MD.

Anke Delie, MD.

Nicolas Kint, MD.

Willem Daneels, MD.

Thomas De Corte, MD.

Philippe Decruyenaere, MD.

03.OVERVIEW

Overview Clinical Trials according
target disease

ALCL - Anaplastic Large-Cell Lymphoma

TRIAL NAME	TITLE	STUDY POPULATION	SC	PI	AVAILABILITY
BIA-ALCL	Breast Implant-associated Anaplastic Large Cell Lymphoma (BIA-ALCL) Registry	Adults with breast implant - associated ALCL	Saskia	Prof. Offner	Open

ALL - Acute Lymphocytic Leukemia

TRIAL NAME	TITLE	STUDY POPULATION	SC	PI	AVAILABILITY
DSP-5336-101	A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP-5336 in Adult Acute Leukemia Patients with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation	R/R ALL with MLLr	Katrien	Dr. Delie	Open

AML - Acute Myeloid Leukemia

TRIAL NAME	TITLE	STUDY POPULATION	SC	PI	AVAILABILITY
75276617AML3001	A Phase 3 Randomized, Double-blind, Placebo-controlled, Study of Bleximenib, Venetoclax and Azacitidine for the Treatment of Participants with Newly Diagnosed Acute Myeloid Leukemia Harboring KMT2ARearrangements or NPM1Mutations who are Ineligible for Intensive Chemotherapy	ND NPM1/KMT2A AML unfit for chemo	Katrien	Dr. Delie	Open
HOVON 173	Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy	ND IDH1+ AML unfit for chemo	Katrien	Dr. Delie	Open
HOVON 177	Randomized study to assess revumenib in combination with azacitidine + venetoclax in adult patients with newly diagnosed NPM1-mutated or KMT2A-rearranged AML ineligible for intensive chemotherapy	ND NPM1/KMT2A unfit for chemo	Katrien	Dr. Delie	Open
HOVON 181	Bleximenib or Placebo in Combination with Standard Induction and Consolidation Therapy followed by Maintenance for the Treatment of Patients with Newly Diagnosed KMT2A rearranged or NPM1-mutant Acute Myeloid Leukemia Eligible for Intensive Chemotherapy	ND NPM1/KM2TA AML fit for chemo	Katrien	Dr. De Corte	Open
SNDX-5613-0710	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Revumenib in Combination with Intensive Chemotherapy in Participants with Newly Diagnosed AML with an NPM1 mutation	ND NPM1 AML fit for chemo	Katrien	Dr. De Corte	Open
DSP-5336-101	A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP-5336 in Adult Acute Leukemia Patients with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation	R/R AML with MLLr or NPM1m	Katrien	Dr. Delie	Open

CLL - Chronic Lymphatic Leukemia

TRIAL NAME	TITLE	STUDY POPULATION	SC	PI	AVAILABILITY
J2N-MC-JZNX	A Phase 2, Open-Label, Randomized Study Evaluating the Efficacy and Safety of 3 Doses of Pirtobrutinib in Participants with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Who Previously Received Treatment with a Covalent Bruton Tyrosine Kinase Inhibitor	ND (17 p del)	Sofie	Prof. Offner	Open
BGB-16673-304	A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma.	R/R CLL / SLL	Saskia	Dr. Daneels	Open
GLORA-1	A Global Multicenter, Open Label, Randomized Phase 3 Registrational Study of Lisafoclax (APG-2575) in Previously Treated Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	R/R CLL with min 1-3 prior line with previous acalabrutinib	Sofie	Prof. Offner	Open

CML - Chronic Myeloid Leukemia

TRIAL NAME	TITLE	STUDY POPULATION	SC	PI	AVAILABILITY
ELVN-001-101	A Phase 1a/1b Study of ELVN-001 for the Treatment of Chronic Myeloid Leukemia	R/R CML	Lieselot	Dr. Mazure	Open

DLBCL - Diffuse Large B-Cell Lymphoma

TRIAL NAME	TITLE	STUDY POPULATION	SC	PI	AVAILABILITY
OLYMPIA-3	Phase 3, open label, randomized study comparing the efficacy And safety of odronextamab (regn1979), an anti-CD20 × anti-CD3 Bispecific antibody, in combination with chop (O-CHOP) versus Rituximab in combination with chop (R-CHOP) in previously Untreated participants with diffuse large b-cell lymphoma	ND DLBCL	Saskia	Prof. Offner	Part 2 vanaf Q2 2026
Soundtrack D2	AZD0486 1L Therapy for Elderly or Unfit Participants with LBCL	ND elderly or unfit LBCL	Sofie	Dr. Daneels	Open Part 2 Q3 2026
GCT3013-03	A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody®-CD3 X CD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia	Richter's Syndrome inegible for chemoimmunotherapy (no CD3xCD20 BITE)	Saskia	Prof. Offner	On Hold
ADCT-402-105 (LOTIS-7)	A Phase 1b Open-Label Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination with Other Anti-cancer Agents in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma	R/R DLBCL/HGBL	Sofie	Prof. Offner	Slot reservation
BP43015	A phase IB, open-label, dose-escalation, multicenter study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of Subcutaneous glofitamab following obinutuzumab pretreatment in patients with relapsed or refractory b-cell non-hodgkin lymphoma	R/R DLBCL with min 2 prior lines (no CD3xCD20 BITE)	Saskia	Prof. Offner	Slot reservation

FL - Follicular Lymphoma

TRIAL NAME	TITLE	STUDY POPULATION	SC	PI	AVAILABILITY
OLYMPIA-2	A phase 3, open-label, randomized study to compare the Efficacy and safety of odronextamab (regn1979), an anticd20 X anti-cd3 bispecific antibody, combined with Chemotherapy versus rituximab combined with Chemotherapy in previously untreated participants With follicular lymphoma	Untreated FL	Saskia	Dr. De Vriendt	On Hold
Morninglyte	A Phase III randomized, open-label, international, multicenter study evaluating the efficacy and safety of mosunetuzumab plus lenalidomide in comparison to anti-CD20 monoclonal antibody plus chemotherapy in subjects with previously untreated FLIPI 2-5 follicular lymphoma	Untreated FL	Saskia	Dr. De Vriendt	Open
OLYMPIA-5	A phase 3, open label, randomized study to compare the efficacy and safety of odronextamab (regn1979), an anti-CD20 x anti-CD3 bispecific antibody, in combination with lenalidomide versus rituximab in combination with lenalidomide in relapsed/refractory participants with follicular lymphoma and marginal zone lymphoma	R/R FL with 1 prior line	Saskia	Dr. De Vriendt	Open

Mastocytosis

TRIAL NAME	TITLE	STUDY POPULATION	SC	PI	AVAILABILITY
Blu-263-1201	A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis	Mastocytosis	Lieselot	Dr. Mazure	Open

MDS - Myelodysplastic Syndromes

TRIAL NAME	TITLE	STUDY POPULATION	SC	PI	AVAILABILITY
Gloria-4	A Global Multicenter, Double-blind, Randomized, Registrational Phase 3 Study of Lixaftoclax (APG-2575) in Combination with Azacitidine (AZA) in Patients with Newly Diagnosed Higher Risk Myelodysplastic Syndrome (HR-MDS)	ND HR-MDS	Lieselot	Dr. Mazure	Open

MF - Myelofibrosis

TRIAL NAME	TITLE	STUDY POPULATION	SC	PI	AVAILABILITY
XPORT-MF-044	A phase 2 study to evaluate the efficacy and safety of selinexor monotherapy in subjects with jak inhibitor naïve myelofibrosis and moderate thrombocytopenia	MF, JAK-inh naïve	Lieselot	Dr. Mazure	Open
BBI-TP-3654-102	A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral Nuvisertib (TP-3654) in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis	MF, R/R to JAKI or ineligible for JAKI	Lieselot	Dr. Mazure	Open

MM - Multiple Myeloma

TRIAL NAME	TITLE	STUDY POPULATION	SC	PI	AVAILABILITY
Majestec-7	A phase 3 randomized study comparing teclistamab in combination with daratumumab sc and lenalidomide (Tec-DR) and talquetamab in combination with daratumumab sc and lenalidomide (Tal-DR) versus daratumumab sc, lenalidomide, and dexamethasone (DRd) in participants with newly diagnosed multiple myeloma who are either ineligible or not intended for autologous stem cell transplant as initial therapy	Newly diagnosed MM Transplant ineligible	Saskia	Dr. Kint	Open
WES and OGM in MM	Genomic profiling for improved risk stratification and personalized treatment in newly diagnosed multiple myeloma	Newly diagnosed MM (transplant eligible and ineligible)	Valerie	Dr. Kint	Open
IMMproved	Positron emission tomography with innovative laboratory techniques for improved risk and disease assessment in myeloma	Newly diagnosed MM Transplant eligible	Valerie	Dr. Kint	Open
Quintessential-2	A Phase 3 Study of a GPRC5D-directed CAR T Cell Therapy in Participants with Relapsed or Refractory Multiple Myeloma and exposed to Lenalidomide.	1-3 prior lines LEN exposed post aBCMA allowed	Valerie	Dr. Kint	Slot reservation
79635322MMY1001	A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-79635322, a Humanized GPRC5D x BCMA x CD3 Trispecific Antibody, in Subjects with Relapsed or Refractory Multiple Myeloma	min 2 prior lines PI, IMiD, aCD38 exposed	Nathalie	Dr. Kint	Slot reservation
CAMMA-3	An open-label, multicenter, phase 1b trial evaluating the safety, pharmacokinetics, and activity of subcutaneous cevostamab in patients with relapsed or refractory multiple myeloma	no appropriate therapy	Nathalie	Dr. Kint	Slot reservation
M25-275	A Phase 1/2, Open-Label, Platform Study to Evaluate Safety and Efficacy of the BCL-2 Inhibitor ABBV-453 given as Monotherapy or in Combination with Antimyeloma Regimens in Subjects with Multiple Myeloma	3-5 lines PI, IMiD, aCD38 exposed	Nathalie	Dr. Decruyenaere	Slot reservation
BIONIC	Prospective observational study on the clinical efficacy of bispecific antibodies in patients with relapsed and refractory multiple myeloma	Observational trial patients treated with Tec or Tal	Nathalie	Dr. Kint	Open

MZL - Marginal Zone Lymphoma

TRIAL NAME	TITLE	STUDY POPULATION	SC	PI	AVAILABILITY
OLYMPIA- 5	A phase 3, open label, randomized study to compare the efficacy and safety of odronextamab (regn1979), an anti-CD20 x anti-CD3 bispecific antibody, in combination with lenalidomide versus rituximab in combination with lenalidomide in relapsed/refractory participants with follicular lymphoma and marginal zone lymphoma	R/R MZL with 1 prior line	Saskia	Dr. De Vriendt	On Hold
MARSUN	Phase III, multicenter, open label, randomized, controlled study investigating mosunetuzumab-lenalidomide versus investigator choices in patients with relapsed or refractory marginal zone lymphoma	MZL with 1-3 prior lines	Sofie	Dr. De Vriendt	Open

SCT - Stem Cell Transplantation

TRIAL NAME	TITLE	STUDY POPULATION	SC	PI	AVAILABILITY
BHS-TJBI703	Allogeneic hematopoietic cell transplantation from HLA-matched donor after Flu-Mel-PTCy versus Flu-Mel-ATG reduced-intensity conditioning: a phase II randomized study from the BHS	Adults receiving RIC	Katrien	Prof. Kerre	Open
TRACE	Treatment of chemo-refractory viral infections after allogeneic stem cell transplantation with multispecific T cells against CMV, EBV and AdV: A phase III, prospective, multicentre clinical trial	CMV/EBV reactivation after transplant	Katrien	Prof. Kerre	Open
Phoebus	A multi-center randomized, double blinded phase IIb trial evaluating oral pooled fecal microbiotherapy MaaT033 to prevent allogeneic hematopoietic cell transplantation complications	Allo-SCT with prior wide-spectrum antibiotics use	Katrien	Dr. Delie	Open

TCL - T-cell Lymphoma

TRIAL NAME	TITLE	STUDY POPULATION	SC	PI	AVAILABILITY
Transcript	An open label, controlled, randomized study evaluating the benefit of autologous stem cell transplantation after complete response in frontline setting patients with T Cell Lymphoma	untreated TCL	Saskia	Dr. De Vriendt	Open
SBI-0145-304 (Terzo)	A multicentre, open-label, Phase 3, randomised controlled trial of duvelisib versus investigator's choice of gemcitabine or bendamustine in patients with relapsed/refractory nodal T cell lymphoma with T follicular helper (TFH) phenotype	R/R TCL with at least 1 prior line	Sofie	Dr. De Vriendt	Open